A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Patients in Canada

Withdrawn before enrolling

Conditions studied: Uterine Fibroids

In brief

This is a non-interventional, cross-sectional survey study to evaluate the effectiveness of the Additional Risk Minimization Measures for Fibristal among Patients in Canada.

Key facts

Study ID

NCT04567095

Run by

Allergan

People needed

0

Starts

2020-10-31

Expected to finish

2021-06-30

Last updated by the study team

2020-10-23

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patients who have received Fibristal within 6 months of completing the survey.
• Patients who have provided permission to share their responses in aggregate with Health Canada.
• Patients who have provided informed consent for their participation in the survey.

You may not qualify if…

• Patients who participated in the cognitive pre-testing of the survey questionnaire to be used for the study.
• Patients who have been direct employees of Allergan, ICON, Health Canada, or Professional Targeted Marketing (PTM) within the past year.

Where it is running

• Clinical Trials Registry Team — Irvine, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.